SYDNEY, Jan 20, 2026, 17:42 AEDT — Market closed
- Wesfarmers shares closed up, outperforming the softer local market
- Investors are eyeing the Feb. 19 half-year results for fresh insights on retail and health sectors
- Priceline franchise news has thrust the health division back into the spotlight for traders
Wesfarmers Ltd shares ended Tuesday 0.8% higher at A$83.33, bucking the broader Australian market’s downward trend.
The retailer set Feb. 19 as the date for its 2026 half-year results, marking the next key event for the stock after a solid start to the year.
The S&P/ASX 200 dropped 0.66% to 8,815.9, dragged down by banks and miners as investors pulled back from risk.
Global markets tensed up again as U.S. President Donald Trump threatened new tariffs over a Greenland-related dispute, driving traders toward safer assets.
Wesfarmers investors are zeroing in on its health division following a new report from the Australian Financial Review that shed light on the downfall of Infinity Pharmacy Group, a major Priceline franchisee.
Wesfarmers Health’s chief customer officer, Richard Pearson, told franchisees in December the group had “worked tirelessly” with Infinity amid “significant financial challenges,” but admitted the situation had grown “untenable.” Pharmacy Daily
KPMG’s creditor update reveals that on Dec. 17, 2025, receivers and managers took control of Infinity Pharmacy Group entities, while Teneo was brought in as voluntary administrators.
Media reports estimate Infinity’s debt tops A$400 million, with around A$110 million owed to Wesfarmers. This has sparked concerns over potential losses for the parent company’s wholesale exposure and the impact on brand economics.
Wesfarmers’ half-year report will offer investors a crucial update on trading at Bunnings and Kmart, while also revealing if management sees any fallout in its health business due to franchise pressures.
On Jan. 28, the Australian Bureau of Statistics releases December-quarter CPI, the main inflation gauge that can quickly sway rate expectations and retail sentiment.
The Priceline situation remains complicated. Should store results weaken or support expenses climb, investors might begin factoring in a bigger downside for the health division than the stock’s current valuation suggests.
Traders are set to focus on the RBA’s early-February meeting for clues on interest rates. Then all eyes will shift to the company’s Feb. 19 results, looking for updates on retail demand, margins, and any provisions related to the pharmacy network.
